Effect of the novel senolytic drug, BCL-xL-PROTAC, on small airway fibroblasts in COPD

Justine Devulder; Peter Fenwick; May Al‐Sahaf; Patrizia Viola; Neetu Razdan; Raphaël Lemaire; Lina Odqvist; Louise Donnelly; Peter J Barnes

doi:10.1183/13993003.congress-2025.pa3533

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2024

Effect of the novel senolytic drug, BCL-xL PROTAC, on small airway epithelial cells in COPD

Justine Devulder, Peter Fenwick, May Al Sahaf, Patrizia Viola, Neetu Razdan, Raphaël Lemaire, Lina Odqvist, Louise Donnelly, Peter J Barnes

Article2025

BCLXL-PROTAC as a senolytic therapy in COPD alveolar type II cells

Yiling Guo, Peter Fenwick, Louise Donnelly, Peter J Barnes

Article2023

P208 Extracellular vesicles from COPD small airway fibroblasts spread senescence to healthy fibroblasts

John Davey, P.S. Fenwick, Peter J Barnes, JV Devulder, LE Donnelly

Article2014

Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer

Yohann Loriot, Pierre Mordant, Delphine Dugué, Olivier Geneste, Andrea Gombos, Paule Opolon, Jean‐François Guégan, Jean‐Luc Perfettini, Alain Pierré, L. Kraus Berthier, Guido Guido Kroemer, Jean‐Charles Soria, Stéphane Depil, Éric Deutsch

Article2024

S150 Effects of putative senotherapies, fisetin and navitoclax, on senescent small airway fibroblasts in COPD

Kara S. Cox, P.S. Fenwick, JV Devulder, Peter J Barnes, LE Donnelly